Advancements and Challenges in Triple-negative Breast Cancer: a Comprehensive Review of Therapeutic and Diagnostic Strategies

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Jun 12

PMID 38863622

Authors

Nating Xiong

Heming Wu

Zhikang Yu

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) poses significant challenges in oncology due to its aggressive nature, limited treatment options, and poorer prognosis compared to other breast cancer subtypes. This comprehensive review examines the therapeutic and diagnostic landscape of TNBC, highlighting current strategies, emerging therapies, and future directions. Targeted therapies, including PARP inhibitors, immune checkpoint inhibitors, and EGFR inhibitors, hold promise for personalized treatment approaches. Challenges in identifying novel targets, exploring combination therapies, and developing predictive biomarkers must be addressed to optimize targeted therapy in TNBC. Immunotherapy represents a transformative approach in TNBC treatment, yet challenges in biomarker identification, combination strategies, and overcoming resistance persist. Precision medicine approaches offer opportunities for tailored treatment based on tumor biology, but integration of multi-omics data and clinical implementation present challenges requiring innovative solutions. Despite these challenges, ongoing research efforts and collaborative initiatives offer hope for improving outcomes and advancing treatment strategies in TNBC. By addressing the complexities of TNBC biology and developing effective therapeutic approaches, personalized treatments can be realized, ultimately enhancing the lives of TNBC patients. Continued research, clinical trials, and interdisciplinary collaborations are essential for realizing this vision and making meaningful progress in TNBC management.

Citing Articles

Development of a prognostic model based on the ceRNA network in Triple-Negative Breast cancer.

Zhu Y, Wang J, Xu B PeerJ. 2025; 13:e19063.

PMID: 40034665 PMC: 11874946. DOI: 10.7717/peerj.19063.

A novel formula to improve the accuracy and prognostic ability of determining the survival time after recurrent breast cancer.

Nishimura R, Sagara Y, Mitsueda R, Taira T, Miyaki T, Kanemitsu S Breast Cancer. 2025; .

PMID: 39964590 DOI: 10.1007/s12282-025-01677-8.

Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine.

Khan S, Jandrajupalli S, Bushara N, Raja R, Mirza S, Sharma K Cells. 2025; 13(24).

PMID: 39768216 PMC: 11674573. DOI: 10.3390/cells13242126.

Impact of Neoadjuvant Therapy on PD-L1 Expression in Triple-Negative Breast Cancer and Correlation with Clinicopathological Factors.

Ilieva N, Pencheva M, Hadzhiev H, Tashkova D, Daskalova E, Georgiev P Diagnostics (Basel). 2024; 14(23).

PMID: 39682581 PMC: 11639797. DOI: 10.3390/diagnostics14232672.

Combinatory Effect of Pequi Oil ()-Based Nanoemulsions Associated to Docetaxel and Anacardic Acid () in Triple-Negative Breast Cancer Cells In Vitro.

Ombredane A, Martins N, de Souza G, Araujo V, Szlachetka I, da Silva S Pharmaceutics. 2024; 16(9).

PMID: 39339206 PMC: 11435098. DOI: 10.3390/pharmaceutics16091170.

References

Nedeljkovic M, Damjanovic A . Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells. 2019; 8(9). PMC: 6770896. DOI: 10.3390/cells8090957. View

Li Y, Su P, Wang Y, Zhang H, Liang Y, Zhang N . Impact of histotypes on preferential organ-specific metastasis in triple-negative breast cancer. Cancer Med. 2019; 9(3):872-881. PMC: 6997059. DOI: 10.1002/cam4.2759. View

Zhou X, Ni Y, Liang X, Lin Y, An B, He X . Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Front Immunol. 2022; 13:915094. PMC: 9520263. DOI: 10.3389/fimmu.2022.915094. View

Addanki S, Meas S, Sarli V, Singh B, Lucci A . Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers. Int J Mol Sci. 2022; 23(14). PMC: 9315812. DOI: 10.3390/ijms23147843. View

Chehelgerdi M, Chehelgerdi M, Allela O, Pecho R, Jayasankar N, Rao D . Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023; 22(1):169. PMC: 10561438. DOI: 10.1186/s12943-023-01865-0. View

Lin Y, Chidley P, Admojo L, Jassal S, Zantuck N, Foroudi F . Pathologic Complete Response and Oncologic Outcomes in Locally Advanced Breast Cancers Treated With Neoadjuvant Radiation Therapy: An Australian Perspective. Pract Radiat Oncol. 2023; 13(4):301-313. DOI: 10.1016/j.prro.2022.12.004. View

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

Thompson K, Leon-Ferre R, Sinnwell J, Zahrieh D, Suman V, Metzger F . Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. NAR Cancer. 2022; 4(2):zcac018. PMC: 9204893. DOI: 10.1093/narcan/zcac018. View

Ahn S, Kim S, Kim C, Jeong J . Molecular Classification of Triple-Negative Breast Cancer. J Breast Cancer. 2016; 19(3):223-230. PMC: 5053306. DOI: 10.4048/jbc.2016.19.3.223. View

10.

Asleh K, Riaz N, Nielsen T . Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. J Exp Clin Cancer Res. 2022; 41(1):265. PMC: 9434975. DOI: 10.1186/s13046-022-02476-1. View

11.

Aysola K, Desai A, Welch C, Xu J, Qin Y, Reddy V . Triple Negative Breast Cancer - An Overview. Hereditary Genet. 2014; 2013(Suppl 2). PMC: 4181680. DOI: 10.4172/2161-1041.S2-001. View

12.

Mustacchi G, De Laurentiis M . The role of taxanes in triple-negative breast cancer: literature review. Drug Des Devel Ther. 2015; 9:4303-18. PMC: 4532347. DOI: 10.2147/DDDT.S86105. View

13.

Rakha E, Reis-Filho J, Ellis I . Impact of basal-like breast carcinoma determination for a more specific therapy. Pathobiology. 2008; 75(2):95-103. DOI: 10.1159/000123847. View

14.

Raimundo L, Calheiros J, Saraiva L . Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target. Cancers (Basel). 2021; 13(14). PMC: 8303227. DOI: 10.3390/cancers13143438. View

15.

Mahmoud R, Ordonez-Moran P, Allegrucci C . Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness. Cancers (Basel). 2022; 14(17). PMC: 9454775. DOI: 10.3390/cancers14174280. View

16.

Geng P, Chi Y, Yuan Y, Yang M, Zhao X, Liu Z . Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer. Front Cell Dev Biol. 2023; 11:1158539. PMC: 10339351. DOI: 10.3389/fcell.2023.1158539. View

17.

Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S . Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022; 15(1):121. PMC: 9422136. DOI: 10.1186/s13045-022-01341-0. View

18.

Exman P, Barroso-Sousa R, Tolaney S . Evidence to date: talazoparib in the treatment of breast cancer. Onco Targets Ther. 2019; 12:5177-5187. PMC: 6612288. DOI: 10.2147/OTT.S184971. View

19.

Medina M, Oza G, Sharma A, Arriaga L, Hernandez Hernandez J, Rotello V . Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. Int J Environ Res Public Health. 2020; 17(6). PMC: 7143295. DOI: 10.3390/ijerph17062078. View

20.

Restrepo J, Duenas D, Corredor Z, Liscano Y . Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment. Cancers (Basel). 2023; 15(13). PMC: 10340640. DOI: 10.3390/cancers15133474. View